Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.

NCT01308437 is registered in ClinicalTrials.gov with Wockhardt as lead sponsor.

NCT NCT01308437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01308437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.
Lead sponsor
Wockhardt
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2011
Completion date
April 30, 2013
Enrollment
134 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

type i diabetes